- Home
- / Voyager Therapeutics
- / Financials
Voyager TherapeuticsHeader placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Financial statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|
| Revenue | 17.3M | 14.2M | 10.1M | 7.6M | 104.4M | 171.1M | 37.4M |
| Revenue growth, % | -18.0% | ||||||
| General and administrative expense | 9.9M | 13.3M | 19.7M | 33.8M | 36.3M | 35.0M | 37.2M |
| Operating expense total | 37.6M | 55.5M | 82.0M | 98.7M | 156.1M | 143.7M | |
| EBITDA | (20.5M) | (41.3M) | |||||
| EBITDA margin, % | -118.5% | -290.4% | |||||
| EBIT | (20.3M) | (41.3M) | (71.9M) | (91.1M) | (51.7M) | 27.4M | (73.6M) |
| EBIT margin, % | -116.8% | -290.4% | -709.1% | -1195.6% | -49.5% | 16.0% | |
| Interest expense | 332.0K | 976.0K | 1.2M | 3.3M | 6.5M | 1.7M | (390.0K) |
| Pre tax profit | (40.1M) | (70.7M) | (88.5M) | (43.6M) | 36.7M | ||
| Income tax expense | 52.0K | (180.0K) | |||||
| Net Income | (29.7M) | (40.2M) | (70.7M) | (88.3M) | (43.6M) | 36.7M | (71.2M) |